J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Agrawal, N. G. B.
Right arrow Articles by Gottesdiener, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agrawal, N. G. B.
Right arrow Articles by Gottesdiener, K. M.

DRUG METABOLISM

The Effects of Modifying In Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity

Nancy G. B. Agrawal, PhD, Catherine Z. Matthews, BS, Ralph S. Mazenko, MS, Eric J. Woolf, PhD, Arturo G. Porras, PhD, Xun Chen, PhD, Jutta L. Miller, BS, Nicole Michiels, BS, Martin Wehling, MD, Armin Schultz, MD, PhD, Alice B. Gottlieb, MD, PhD, Walter K. Kraft, MD, Howard E. Greenberg, MD, MBA, FCP, Scott A. Waldman, MD, PhD, FCP, Sean P. Curtis, MD and Keith M. Gottesdiener, MD

From Merck Research Laboratories, West Point, Pennsylvania (Dr Agrawal, Ms Matthews, Mr Mazenko, Dr Woolf, Dr Porras); Merck Research Laboratories, Rahway, New Jersey (Dr Chen, Ms Miller, Dr Curtis, Dr Gottesdiener); Merck Research Laboratories, Brussels, Belgium (Ms Michiels); Klinische Pharmakologie Mannheim, University of Heidelberg, Germany (Dr Wehling, Dr Schultz); UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey (Dr Gottlieb); and Thomas Jefferson University, Philadelphia, Pennsylvania (Dr Kraft, Dr Greenberg, Dr Waldman). Study funded by Merck & Co, Inc.

To investigate the influence of modifying in vivo cytochrome P450 3A (CYP3A) activity on the pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, and of etoricoxib administration on CYP3A activity, a 3-part, randomized, crossover study was conducted in 3 panels of healthy volunteers. In part I, 8 subjects were administered a single dose of 60 mg etoricoxib alone and following daily doses of 400 mg ketoconazole, a known strong inhibitor of CYP3A. In part II, 8 different subjects were administered a single dose of 60 mg etoricoxib alone and following daily doses of 600 mg rifampin, a known strong inducer of CYP3A. In parts I and II, plasma samples were collected following each etoricoxib dose and analyzed for etoricoxib. In part III, 8 different subjects were administered 120 mg etoricoxib or placebo once daily for 11 days, and the erythromycin breath test was administered on day 11 of each period. Coadministration of etoricoxib with daily doses of ketoconazole resulted in an average 43% increase in etoricoxib AUC; based on previous studies, this increase would not be expected to have any clinically meaningful effect. In contrast, coadministration of etoricoxib with daily doses of rifampin had a potentially clinically important effect on etoricoxib pharmacokinetics (average 65% decrease in etoricoxib AUC). Etoricoxib had no effect on hepatic CYP3A activity, as assessed by the erythromycin breath test.

Key Words: Etoricoxib • drug interactions • CYP3A • ketoconazole • rifampin • erythromycin breath test • cyclooxygenase • COX-2

Address for reprints: Dr Nancy G B Agrawal, Department of Drug Metabolism, WP75-200, Merck Research Laboratories, West Point, PA 19486.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Clinical Pharmacology